Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer
This is a two arm, 2-center, Phase II, study of 5-FU, irinotecan, bevacizumab (FOLFIRI-beva) and hydroxychloroquine (HCQ) in patients with previously untreated metastatic colorectal cancer (mCRC).

Up to 155 patients will be screened for DTP-signature and up to 31 evaluable patients who are determined to be DTP-signature high will be treated with FOLFIRI-beva and HCQ.

Patients will continue to receive treatments until evidence of disease progression, intolerable side effects, withdrawal of consent or death.
Metastatic Colorectal Cancer
DRUG: Hydroxychloroquine|DRUG: Irinotecan|DRUG: Leucovorin|DRUG: Fluorouracil|DRUG: Bevacizumab
Overall response rate, Percentage of participants who have a partial response or complete response to study treatment., Start of study treatment to end of study, up to 48 months.
Progression-free survival, Average length of time that participants' diseases do not worsen., Start of study treatment to time of disease progression, up to 48 months.|Overall survival, Average length of time that participants are alive., Start of study treatment to time of death, up to 48 months.|Incidences and severity of adverse events, Number of adverse events per grade, Start of study treatment to end of study, up to 48 months.
This is a two arm, 2-center, Phase II, study of 5-FU, irinotecan, bevacizumab (FOLFIRI-beva) and hydroxychloroquine (HCQ) in patients with previously untreated metastatic colorectal cancer (mCRC).

Up to 155 patients will be screened for DTP-signature and up to 31 evaluable patients who are determined to be DTP-signature high will be treated with FOLFIRI-beva and HCQ.

Patients will continue to receive treatments until evidence of disease progression, intolerable side effects, withdrawal of consent or death.